安旭生物：2025年净利同比预降55.8%-63.08%

Group 1 - The company Anxu Biotech (688075) expects a significant decline in net profit for 2025, projecting a range of 71 million to 85 million yuan, representing a year-on-year decrease of 55.8% to 63.08% [4] - The expected non-recurring net profit for the same period is estimated to be between 13 million and 15.6 million yuan, indicating a year-on-year decline of 58.84% to 65.7% [4] - As of January 30, the company's price-to-earnings ratio (TTM) is approximately 60.16 to 72.03 times, with a price-to-book ratio (LF) of about 0.99 times and a price-to-sales ratio (TTM) of around 11.05 times [4] Group 2 - The company's main business involves POCT (Point of Care Testing) reagents and instruments [7] - The decline in profit is attributed to several factors, including increased costs due to U.S. tariffs, rising operational expenses from expanding technology platforms, and losses from currency fluctuations [7] - The company is maintaining its competitive advantage by investing in new technology platforms while also expanding its market presence both domestically and internationally [7]